Premium
TRPV1 sustains microglial metabolic reprogramming in Alzheimer's disease
Author(s) -
Lu Jia,
Zhou Wei,
Dou Fangfang,
Wang Chenfei,
Yu Zhihua
Publication year - 2021
Publication title -
embo reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.584
H-Index - 184
eISSN - 1469-3178
pISSN - 1469-221X
DOI - 10.15252/embr.202052013
Subject(s) - microglia , autophagy , pi3k/akt/mtor pathway , innate immune system , protein kinase b , neuroscience , trpv1 , mechanistic target of rapamycin , immune system , biology , reprogramming , microbiology and biotechnology , inflammation , immunology , phosphorylation , signal transduction , cell , receptor , biochemistry , apoptosis , transient receptor potential channel
As the brain‐resident innate immune cells, reactive microglia are a major pathological feature of Alzheimer's disease (AD). However, the exact role of microglia is still unclear in AD pathogenesis. Here, using metabolic profiling, we show that microglia energy metabolism is significantly suppressed during chronic Aβ‐tolerant processes including oxidative phosphorylation and aerobic glycolysis via the mTOR‐AKT‐HIF‐1α pathway. Pharmacological activation of TRPV1 rescues Aβ‐tolerant microglial dysfunction, the AKT/mTOR pathway activity, and metabolic impairments and restores the immune responses including phagocytic activity and autophagy function. Amyloid pathology and memory impairment are accelerated in microglia‐specific TRPV1‐knockout APP/PS1 mice. Finally, we showed that metabolic boosting with TRPV1 agonist decreases amyloid pathology and reverses memory deficits in AD mice model. These results indicate that TRPV1 is an important target regulating metabolic reprogramming for microglial functions in AD treatment.